U.S. markets close in 1 hour 57 minutes

Novartis halts malaria drug trial against COVID-19 amid participant shortfall

John Miller

By John Miller

ZURICH, June 19 (Reuters) - Swiss drugmaker Novartis is halting its trial of malaria drug hydroxychloroquine (HCQ) against COVID-19 after struggling to find participants, it said on Friday, as data from other studies raised doubts about its efficacy.

Novartis's move follows the U.S. Food and Drug Administration's (FDA) decision this week to revoke emergency use authorization for hydroxychloroquine against COVID-19, on grounds that it is unlikely to help patients. (Reporting by John Miller; Editing by Cynthia Osterman)